Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levamlodipine Maleate

FDA-approved product (tablet, oral), marketed as Conjupri.

Registered studies
4
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Levamlodipine Maleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levamlodipine Maleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levamlodipine Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

    NCT05947448 · start 2024-01-22

    Registered record
    Registry ID
    NCT05947448
    Conditions
    Essential Hypertension
    Interventions
    Azilsartan Medoxomil Potassium Tablet; Nifedipine Sustained -release Tablets; Levoamlodipine Maleate Table
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-01-22
    Completion
    2025-12-31
    Enrolment
    1,215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAzilsartan Medoxomil Potassium Tablet; Nifedipine Sustained -release Tablets; Levoamlodipine Maleate Table
    PhaseNot recorded
    Registry statusUnknown

  • Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

    NCT03657550 · start 2018-05-31

    Registered record
    Registry ID
    NCT03657550
    Conditions
    Hypertension
    Interventions
    Levamlodipine, Amlodipine; Amlodipine, Levamlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-31
    Completion
    2018-09-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionLevamlodipine, Amlodipine; Amlodipine, Levamlodipine
    PhasePhase 1
    Registry statusCompleted

  • Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research

    NCT01844570 · start 2013-02

    Registered record
    Registry ID
    NCT01844570
    Conditions
    Primary Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2015-12
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension

    NCT01131546 · start 2009-12

    Registered record
    Registry ID
    NCT01131546
    Conditions
    Essential Hypertension
    Interventions
    Levamlodipine besylate; Amlodipine maleate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-03
    Enrolment
    1,080

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionLevamlodipine besylate; Amlodipine maleate
    PhasePhase 4
    Registry statusCompleted